BUSINESS

• Otsuka Targets Around 2030 US Launch for Transcend’s PTSD Candidate
  April 13, 2026

• Nippon Shinyaku, xFOREST Ink RNA-Targeting Small Molecule Research Pact
  April 13, 2026

• OTC-Like Drug Reform Seen Adding 190 Billion Yen to Japan OTC Market by 2040: Fuji Keizai
  April 13, 2026

• MSD Japan Eyes Up to 8 Approvals, 8-Plus Filings under New Chief
  April 10, 2026

• Japan Pharma Workforce Up Slightly; Generic Firms Drive Gains over 5 Years
  April 10, 2026

• Zenyaku, Chugai to End Rituxan Co-Promotion in September
  April 10, 2026

• Effexor’s GAD Nod Seen Boosting Diagnosis, Treatment in Japan: Expert
  April 10, 2026

• Pfizer Japan Files Tukysa Label Expansion in Breast, Biliary Tract Cancers
  April 9, 2026

• Shionogi Signs US Government Contract to Boost Cefiderocol Supply
  April 9, 2026

• Sumitomo Pharma to Raise up to 116.5 Billion Yen for R&D, Debt Reduction
  April 9, 2026

• Meiji Pharma Asia Launches Operations in Singapore
  April 9, 2026

• Rising Costs Squeeze Generic Firms, Spur Calls for Unprofitable Drug Re-Pricing in 2027
  April 8, 2026

• BMS Files to Fully Localize Breyanzi Production in Japan
  April 8, 2026

• Japan Ethical Drug Sales Surge 7.7% in February: Crecon
  April 8, 2026

• Sanofi to Launch Voluntary Buyout Program, Targets General Medicines Unit
  April 7, 2026

• Toho’s VC Arm Makes First Investment in US AI Antibody Startup
  April 7, 2026

• Keytruda Holds Top Spot for 30 Straight Months in March: Encise
  April 7, 2026

• Drug Makers Keep New Grad Hiring Largely Flat as Sales Rep Hiring Picks Up
  April 6, 2026

• Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
  April 6, 2026

• Expert Highlights Subcutaneous Benefits of Rybrofaz in Lung Cancer
  April 6, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »